Published in BMJ on August 03, 2002
Endocrine disrupters as obesogens. Mol Cell Endocrinol (2009) 2.80
Modern antipsychotic drugs: a critical overview. CMAJ (2005) 1.98
[Psychotropic drugs and diabetes]. Wien Med Wochenschr (2011) 1.40
Minireview: the case for obesogens. Mol Endocrinol (2009) 1.33
How can research ethics committees protect patients better? BMJ (2003) 1.29
Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care (2016) 1.21
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes (2008) 1.19
Efficacy, safety and cost of new drugs acting on the central nervous system. Eur J Clin Pharmacol (2003) 1.11
Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health (2008) 1.06
Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull (2007) 1.05
Psychiatric disorder in early adulthood and risk of premature mortality in the 1946 British Birth Cohort. BMC Psychiatry (2011) 0.94
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology (Berl) (2008) 0.90
Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) (2003) 0.89
Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med (2004) 0.88
Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed (2004) 0.88
Ethnic differences in primary care management of diabetes and cardiovascular disease in people with serious mental illness. Br J Gen Pract (2012) 0.85
Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12 103 individuals with and without contact with psychiatric services. Clin Pract Epidemiol Ment Health (2008) 0.85
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. BMC Psychiatry (2006) 0.83
Arrhythmias and sudden death in patients taking antipsychotic drugs. BMJ (2002) 0.81
[Antipsychotic drug-induced changes in metabolism]. Wien Klin Wochenschr (2006) 0.80
Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers. Br J Clin Pharmacol (2012) 0.78
Risk:benefit assessment of old medicines. Br J Clin Pharmacol (2004) 0.77
Clinical trial design: horses for courses. World Psychiatry (2009) 0.77
Efficacy should drive atypical antipsychotic treatment. BMJ (2003) 0.75
Dr. Masand Replies. Prim Care Companion J Clin Psychiatry (2002) 0.75
Approach to managing behavioural disturbances in dementia. Can Fam Physician (2006) 0.75
Antipsychotic drugs and diabetes. CMAJ (2003) 0.75
An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat (2008) 0.75
Development of diabetes mellitus associated with quetiapine: A case series. Medicine (Baltimore) (2017) 0.75
GLP-1 receptor agonist exenatide restores atypical antipsychotic clozapine treatment-associated glucose dysregulation and damage of pancreatic islet beta cells in mice. Toxicol Rep (2016) 0.75
Do we learn the right things from clinical trials? Eur J Clin Pharmacol (2008) 0.75
The UK General Practice Research Database. Lancet (1997) 10.62
Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry (1999) 8.04
Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med (1995) 7.62
Accuracy of diagnosis of psychosis on general practice computer system. BMJ (1993) 4.88
The General Practice Research Database. Scientific and Ethical Advisory Group. QJM (1998) 4.67
The metabolic effects of epinephrine and related amines. Pharmacol Rev (1956) 2.12
Drugs of the psychopharmacological revolution in clinical psychiatry. Psychiatr Serv (2000) 1.99
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry (2000) 1.67
Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels. Br J Clin Pharmacol (1984) 1.44
Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ (2001) 1.43
Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry (1999) 1.28
The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community. Int J Obes (1989) 1.21
Novel antipsychotics and new onset diabetes. Biol Psychiatry (1998) 1.19
Pharmacologic treatment of schizophrenia. Biol Psychiatry (1999) 1.19
Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism. Am J Obstet Gynecol (1982) 1.05
The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol (2001) 1.02
Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol (1998) 1.00
Phenothiazines and diabetes in hospitalized women. Am J Psychiatry (1968) 1.00
Hyperglycemia and olanzapine. Am J Psychiatry (1999) 0.97
Hyperglycemia associated with olanzapine. J Clin Psychiatry (1998) 0.95
A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry (1988) 0.94
Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharmacol (1988) 0.91
Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry (1999) 0.91
Olanzapine-induced glucose dysregulation. Ann Pharmacother (2001) 0.88
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases. Diabet Med (2000) 0.85
Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care (2007) 12.71
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation (2004) 7.77
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull (2004) 7.58
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med (2002) 5.80
Treating depression in predominantly low-income young minority women: a randomized controlled trial. JAMA (2003) 5.28
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA (2013) 4.98
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69
Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care (2004) 4.57
Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res (2009) 4.13
The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull (2009) 3.78
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull (2009) 2.61
Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain (2009) 2.53
New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation (2002) 2.44
Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis (2004) 2.42
Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology (2002) 2.27
Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis (2005) 2.24
Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 2.23
Hepatitis c in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg (2002) 2.12
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res (2013) 1.96
Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol (2010) 1.89
Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol (2005) 1.87
Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) (2006) 1.87
Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension (2002) 1.86
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care (2012) 1.84
Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol (2007) 1.84
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation (2008) 1.80
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
Vision-specific instruments for the assessment of health-related quality of life and visual functioning: a literature review. Pharmacoeconomics (2002) 1.75
Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry (2006) 1.74
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophr Res (2005) 1.69
Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res (2004) 1.65
Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl (2009) 1.65
Molecular epidemiology of tuberculosis in a low- to moderate-incidence state: are contact investigations enough? Emerg Infect Dis (2002) 1.64
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry (2002) 1.62
Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat (2007) 1.60
The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum (2005) 1.59
The SEEK model of pediatric primary care: can child maltreatment be prevented in a low-risk population? Acad Pediatr (2012) 1.56
Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. Am J Psychiatry (2004) 1.54
Intrafamilial transmission of hepatitis C in Egypt. Hepatology (2005) 1.53
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health (2004) 1.52
Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry (2003) 1.50
Is a family equal to the sum of its parts? Estimating family-level well-being for cost-effectiveness analysis. Qual Life Res (2005) 1.49
Dental visits to hospital emergency departments by adults receiving Medicaid: assessing their use. J Am Dent Assoc (2002) 1.49
Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc (2002) 1.43
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology (2009) 1.41
Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int (2013) 1.41
Commentary on "Critical flaws in the FSFI and IIEF". J Sex Res (2014) 1.40
Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull (2006) 1.39
Galantamine-induced QTc prolongation. J Clin Psychiatry (2006) 1.38
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis (2010) 1.36
Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry (2002) 1.36
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum (2012) 1.34
Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull (2005) 1.34
Somatic healthcare utilization among adults with serious mental illness who are receiving community psychiatric services. Med Care (2003) 1.34
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res (2004) 1.33
The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J (2004) 1.32
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes (2006) 1.31
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
Identifying children at high risk for a child maltreatment report. Child Abuse Negl (2011) 1.29
No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology (2005) 1.29
Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics (2008) 1.29
Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2004) 1.28
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology (2009) 1.28
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry (2010) 1.27
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL. Qual Life Res (2004) 1.26
The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr (2004) 1.26
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry (2011) 1.26
Linking pain items from two studies onto a common scale using item response theory. J Pain Symptom Manage (2009) 1.25
Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clin Proc (2007) 1.24
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics (2005) 1.22
Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol (2002) 1.21
Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol (2002) 1.20
Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2003) 1.18
The impact of diabetic retinopathy: perspectives from patient focus groups. Fam Pract (2004) 1.18
Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology (2013) 1.18
Use of a critical time intervention to promote continuity of care after psychiatric inpatient hospitalization. Psychiatr Serv (2009) 1.18
Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes (2003) 1.17
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry (2006) 1.17
Intellectual property rights and good research practice. Qual Life Res (2009) 1.17
Correlates of severity of smoking among persons with severe mental illness. Am J Addict (2007) 1.16